Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 232

1.

If we build it they will come: targeting the immune response to breast cancer.

Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, Abdul Sater H, Sparano JA, Cescon D, Page DB, McArthur H, Adams S, Mittendorf EA.

NPJ Breast Cancer. 2019 Oct 29;5:37. doi: 10.1038/s41523-019-0133-7. eCollection 2019. Review.

2.

Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors.

Yi M, Lin H, Bedrosian I, Shen Y, Hunt KK, Chavez-MacGregor M, King TA, Mittendorf EA.

Ann Surg Oncol. 2019 Oct 30. doi: 10.1245/s10434-019-07983-8. [Epub ahead of print]

PMID:
31667721
3.

Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, McArthur H, Balko JM, Gameiro SR, Nanda R, Gulley JL, Kalinsky K, White J, Litton J, Chmura SJ, Polley MY, Vincent B, Cescon DW, Disis ML, Sparano JA, Mittendorf EA, Adams S.

NPJ Breast Cancer. 2019 Oct 8;5:34. doi: 10.1038/s41523-019-0130-x. eCollection 2019. Review.

4.

Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach.

Weiss A, Wong S, Golshan M, Freedman RA, Metzger O, Bellon J, Mittendorf EA, King TA.

Ann Surg Oncol. 2019 Sep 27. doi: 10.1245/s10434-019-07785-y. [Epub ahead of print]

PMID:
31562601
5.

Lack of Robust Prognostic Biomarkers for Immunotherapy in Breast Cancer-Adverse Events-In Reply.

Adams S, Mittendorf EA.

JAMA Oncol. 2019 Sep 12. doi: 10.1001/jamaoncol.2019.3605. [Epub ahead of print] No abstract available.

PMID:
31513254
6.

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.

Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK.

J Clin Oncol. 2019 Aug 28:JCO1901304. doi: 10.1200/JCO.19.01304. [Epub ahead of print]

PMID:
31461380
7.

Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.

Hartl CA, Bertschi A, Puerto RB, Andresen C, Cheney EM, Mittendorf EA, Guerriero JL, Goldberg MS.

J Immunother Cancer. 2019 Jul 30;7(1):199. doi: 10.1186/s40425-019-0654-5.

8.

Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis.

Wong SM, Weiss A, Mittendorf EA, King TA, Golshan M.

Ann Surg Oncol. 2019 Oct;26(11):3517-3525. doi: 10.1245/s10434-019-07583-6. Epub 2019 Jul 24.

PMID:
31342389
9.

SentimagIC: A Non-inferiority Trial Comparing Superparamagnetic Iron Oxide Versus Technetium-99m and Blue Dye in the Detection of Axillary Sentinel Nodes in Patients with Early-Stage Breast Cancer.

Alvarado MD, Mittendorf EA, Teshome M, Thompson AM, Bold RJ, Gittleman MA, Beitsch PD, Blair SL, Kivilaid K, Harmer QJ, Hunt KK.

Ann Surg Oncol. 2019 Oct;26(11):3510-3516. doi: 10.1245/s10434-019-07577-4. Epub 2019 Jul 11.

PMID:
31297674
10.

Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.

Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, Shen AH, DeSantis S, Dominici L, Golshan M, Weiss A, Bellon J, Mittendorf EA, King TA.

Ann Surg Oncol. 2019 Oct;26(11):3502-3509. doi: 10.1245/s10434-019-07517-2. Epub 2019 Jun 21.

PMID:
31228134
11.

Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.

Sceneay J, Goreczny GJ, Wilson K, Morrow S, DeCristo MJ, Ubellacker JM, Qin Y, Laszewski T, Stover DG, Barrera V, Hutchinson JN, Freedman RA, Mittendorf EA, McAllister SS.

Cancer Discov. 2019 Sep;9(9):1208-1227. doi: 10.1158/2159-8290.CD-18-1454. Epub 2019 Jun 19.

PMID:
31217296
12.

The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.

Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM.

Clin Cancer Res. 2019 Aug 1;25(15):4644-4655. doi: 10.1158/1078-0432.CCR-19-0173. Epub 2019 May 6.

PMID:
31061067
13.

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA.

Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.

PMID:
31043414
14.

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.

Mittendorf EA, Lu B, Melisko M, Price Hiller J, Bondarenko I, Brunt AM, Sergii G, Petrakova K, Peoples GE.

Clin Cancer Res. 2019 Jul 15;25(14):4248-4254. doi: 10.1158/1078-0432.CCR-18-2867. Epub 2019 Apr 29.

PMID:
31036542
15.

Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes.

Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF.

Breast Cancer Res Treat. 2019 Jul;176(2):435-444. doi: 10.1007/s10549-019-05243-7. Epub 2019 Apr 25.

PMID:
31025270
16.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
17.

Investigation of parameters that determine Nano-DC vaccine transport.

Zhang J, Mai J, Li F, Shen J, Zhang G, Li J, Hinkle LE, Lin D, Liu X, Li Z, Wang RF, Mittendorf EA, Ferrari M, Shen H.

Biomed Microdevices. 2019 Apr 4;21(2):39. doi: 10.1007/s10544-019-0397-6.

18.

Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come.

Mittendorf EA, King TA.

Ann Surg Oncol. 2019 May;26(5):1173-1175. doi: 10.1245/s10434-019-07240-y. Epub 2019 Feb 24. No abstract available.

PMID:
30798446
19.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM.

Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047.

PMID:
30753274
20.

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.

PMID:
30702028

Supplemental Content

Loading ...
Support Center